Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces HbA1c (by 1.7–2.4%) and body weight (up to 22.5%) in patients with type 2 diabetes compared to placebo, semaglutide, and insulin therapies.
Tirzepatide is a once-weekly injection for type 2 diabetes that significantly lowers blood sugar and promotes substantial weight loss. It starts at a low dose (2.5 mg) to minimize stomach issues, then increases every 4 weeks up to 15 mg. It is more effective for weight loss and A1C reduction than insulin or semaglutide in head-to-head trials. Common side effects are gastrointestinal (nausea, diarrhea) but are usually mild. It is contraindicated for those with a history of medullary thyroid carcinoma.
Across the SURPASS research program trials, tirzepatide lowered A1C by 1.7–2.4% from baseline... Patients in the treatment groups averaged a weight loss of 5.44–11.34 kg (12–25 lb)... Across all trials, patients on tirzepatide 15 mg lost 8.8–12.9 kg (19.4–28.44 lb) or 9.17–13.7% body weight.
Why this rating
Based on multiple Phase 3 randomized controlled trials (SURPASS 1-5) with large sample sizes and statistically significant results.
Source
Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin
Alexis V. Fanshier et al. · Clinical Diabetes · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →